The analysts, on average, are forecasting a $135 price target, but the stock is already up 38.54% from its recent lows. OppenheimerFunds Inc. owned about 1.22% of Zimmer Biomet Holdings worth $298,560,000 as of its most recent filing with the SEC.
The actual size of Jana's stake in the company is not yet clear, nor are the hedge fund's plans.
Zimmer Biomet Holdings, Inc. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider's stock valued at $2,044,168,000 after buying an additional 16,336,262 shares in the last quarter. Finally, Acuta Capital Partners LLC bought a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $1,548,000. The legal version of this story can be accessed at https://sportsperspectives.com/2017/07/16/oppenheimerfunds-inc-lowers-position-in-zimmer-biomet-holdings-inc-zbh-updated-updated.html. Janus Capital Management LLC boosted its position in shares of Zimmer Biomet Holdings by 157.0% in the fourth quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider's stock worth $128,643,000 after buying an additional 734,500 shares in the last quarter.
Shares of Zimmer Biomet Holdings, Inc.
Shares of Zimmer Biomet Holdings (NYSE:ZBH) opened at 132.49 on Friday.
The most current P/E ratio is 54.23 and market cap is 26.72B.
The company has a one year high of $133.21 and a one year low of $95.63. The stock has a 50 day moving average of $123.43 and a 200-day moving average of $117.75.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, April 27th. The latest reports which are outstanding on Monday 17th of July state 10 analysts have a rating of "strong buy", 8 analysts "buy", 8 analysts "neutral", 1 analysts "sell" and 1 analysts "strong sell". Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. The business had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.96 billion. They expect $0.16 EPS, up 6.67% or $0.01 from last year's $0.15 per share. Breaking that down further, it has performed 4.23% for the week, 5.49% for the month, 10.84% over the last quarter, 15.78% for the past half-year and 4.91% for this previous year. Currently, Zimmer Biomet Holdings has an average volume of 603.5K.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 28th. Cleararc Capital Inc. boosted its position in shares of Zimmer Biomet Holdings by 0.5% in the first quarter. This represents a $0.96 annualized dividend and a yield of 0.72%. The ex-dividend date has been established as Wednesday the 21st of June 2017.
02/01/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Robert W. Baird. If you are accessing this report on another domain, it was illegally stolen and republished in violation of global copyright legislation.
A number of equities analysts have weighed in on ZBH shares. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) has "Neutral" rating given on Tuesday, November 8 by Northcoast. The company's shares closed yesterday at $132.49, close to its 52-week high of $133.21. Canaccord Genuity restated a "buy" rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a report on Friday. Piper Jaffray Companies reissued a "buy" rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday. Stifel Nicolaus reiterated a "hold" rating and issued a $125.00 price target on shares of Zimmer Biomet Holdings in a report on Friday. They now have a Dollars 137 price target on the stock. Also, insider David C. Dvorak sold 87,331 shares of the company's stock in a transaction dated Thursday, April 27th. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Chad F. Phipps sold 6,200 shares of the company's stock in a transaction on Friday, May 5th. Last month, Sang Yi, the President of ZBH sold 17,731 shares for a total of $2,208,490. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 111,262 shares of company stock worth $13,103,927.
Zimmer Biomet Holdings, Inc., launched on January 12, 2001, is involved in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.